Neuronetics Inc (NASDAQ:STIM) has been given an average rating of “Buy” by the six analysts that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $34.50.

A number of equities analysts have issued reports on STIM shares. JMP Securities increased their price target on Neuronetics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 15th. William Blair started coverage on Neuronetics in a research report on Monday, July 23rd. They set an “outperform” rating on the stock. Piper Jaffray Companies started coverage on Neuronetics in a research report on Monday, July 23rd. They set an “overweight” rating on the stock. BTIG Research reiterated a “buy” rating and set a $33.00 price target on shares of Neuronetics in a research report on Wednesday, November 7th. Finally, Canaccord Genuity increased their price target on Neuronetics from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, August 15th.

Several institutional investors have recently made changes to their positions in the business. Alpine Woods Capital Investors LLC raised its holdings in shares of Neuronetics by 40.0% during the third quarter. Alpine Woods Capital Investors LLC now owns 14,000 shares of the company’s stock valued at $449,000 after acquiring an additional 4,000 shares during the last quarter. American International Group Inc. acquired a new position in shares of Neuronetics during the third quarter valued at approximately $136,000. Victory Capital Management Inc. acquired a new position in shares of Neuronetics during the second quarter valued at approximately $133,000. Pier Capital LLC acquired a new position in shares of Neuronetics during the second quarter valued at approximately $186,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Neuronetics during the third quarter valued at approximately $284,000. 60.78% of the stock is owned by institutional investors and hedge funds.

STIM stock traded down $1.03 during mid-day trading on Friday, reaching $17.55. 162,649 shares of the company’s stock were exchanged, compared to its average volume of 107,828. The company has a current ratio of 7.63, a quick ratio of 7.46 and a debt-to-equity ratio of 0.33. Neuronetics has a 12-month low of $18.01 and a 12-month high of $39.39.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Tuesday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.11. The business had revenue of $13.74 million for the quarter, compared to analysts’ expectations of $12.68 million. On average, equities analysts predict that Neuronetics will post -1.88 earnings per share for the current year.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.

Featured Article: What is a Call Option?

Analyst Recommendations for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.